Louisiana 2016 2016 Regular Session

Louisiana Senate Bill SB117 Comm Sub / Analysis

                    The original instrument was prepared by Christine Arbo Peck. The following digest,
which does not constitute a part of the legislative instrument, was prepared by Mary
Dozier O'Brien.
DIGEST
SB 117 Reengrossed 2016 Regular Session	Mills
Present law includes legislative intent that was added in 2006 after implementation of Medicare Part
D and post-Hurricane Katrina. Proposed law removes present law. 
Present law includes a restriction on implementation of provisions of present law for a period of six
months after June 13, 2001. Proposed law removes present law.
Present law includes provisions that were sunset by subsequent law. Proposed law removes the
provisions that were sunset.
Present law requires membership of the committee to be selected from a list of three names
submitted by each represented organization. Proposed law allows each represented organization to
submit one name as their representative.
Present law provides that two practicing pharmacists shall be selected from a list of names 
submitted by the Louisiana Pharmacists Association. Proposed law changes the committee
appointment members for the two practicing pharmacist positions to require that one member shall
be an independent pharmacist recommended by the Louisiana Independent Pharmacies Association
and one member shall be a pharmacist representing a chain pharmacy recommended by the Louisiana
Pharmacists Association.
Present law refers to the Medicaid pharmacy drug list as a pharmacopia. Proposed law changes the
reference to preferred drug list.
Present law provides that new drugs are available on the pharmacopia as soon as they are approved
by the USDA and commercially available. Proposed law states that new drugs may be added when
approved by the USDA and the manufacturer enters into a federal medicaid drug rebate program if
the department determines it is in the best interest of the medical assistance program.
Proposed law clarifies that when a new drug reviewed by the committee is approved by the FDA,
it shall be reviewed at the next committee meeting.
Effective upon signature of the governor or lapse of time for gubernatorial action.
(Amends R.S. 46:153.3(B)(2)(a)(iv), (D)(2)(intro para), (D)(2)(c), (d), (e), (f), (g), (h), (k), and (p),
and (D)(5)(b) and (c); repeals R.S. 46:153.3(B)(1)(b), (c), (d), and (e), (B)(2)(d), (B)(3) and (4),
(C)(2) and (3), and (D)(5)(d) and (e)) Summary of Amendments Adopted by Senate
Committee Amendments Proposed by Senate Committee on Health and Welfare to the
original bill
1. Changes the committee appointment members for the two practicing pharmacist
positions to require that one member shall be an independent pharmacist
recommended by the Louisiana Independent Pharmacies Association and one
member shall be a pharmacist representing a chain pharmacy recommended by the
Louisiana Pharmacists Association.
2. Clarifies that when a new drug is approved by the FDA, it shall be reviewed for
consideration by the committee at their next scheduled meeting for consideration of
inclusion on the preferred drug list.
3. Makes technical changes.
Senate Floor Amendments to engrossed bill
1. Adopted amendments from Legislative Bureau note that were purely technical.